Sixty-nine ( 41 % ) of 169 patients receiving pegloticase developed high titer anti-pegloticase Ab ( > 1:2430 ) and 40 % ( 67/169 ) developed anti-PEG Ab ; 1 patient receiving placebo developed high titer anti-pegloticase Ab .